Drug Trial Radar · NCT00756509
Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib
Last checked: Nov 20, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
34
Actual
Start
Aug 29, 2008
Primary completion
Dec 18, 2024
Study completion Dec 18, 2024
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Sep 22, 2008
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this multicenter, single-arm, phase II trial is to evaluate the efficacy of Nilotinib in patients with unresectable or metastatic gastrointestinal stromal tumors (GIST).
Conditions
- Gastrointestinal Stromal Tumors
Interventions
NilotinibDrug
800 mg/d orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Participants With Best Overall Response at Month 6 (Core Phase) Determined According to the RECIST v1.0.Time frame: from baseline to month 6, core phase
Locations
10 sites in 5 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Helsinki, Finland
Novartis Investigative Site
Lyon, France
Novartis Investigative Site
Bad Saarow, Germany
Novartis Investigative Site
Essen, Germany
Novartis Investigative Site
Hanover, Germany
Novartis Investigative Site
Munich, Bavaria, Germany
Novartis Investigative Site
Milan, MI, Italy
Novartis Investigative Site
Palma, Balearic Islands, Spain
Novartis Investigative Site
L'Hospitalet de Llobregat, Barcelona, Spain
Novartis Investigative Site
Valencia, Valencia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.